PRKAB2 and thrombocytopenic purpura: This may contribute to explain the relationship between ZFP90 and PRKAB2. PRKAB2 is also one of the target genes of Fostamatinib that is a drug approved by the US Food and Drug Administration (FDA) in 2018 for the treatment of idiopathic thrombocytopenic purpura.